2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 260-262
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human
PAPER

107 Phase 2 study of birelentinib (DZD8586) monotherapy for treatment-Naïve and relapse/refractory patients with CLL/SLL (TAI-SHAN8)

Wei Yang, Keshu Zhou, PhD2, Huayuan Zhu, MD, PhD3, Tingyu of Wang4, Xutao Guo, MD, PhD5, Jian-Qing Mi6, Sujun Gao, MD7, Yun Zhuang8, Ying Xiang9, Kaiyang Ding, MD10, Liping Su, MD11, Huili Cai12, Guohui Cui13, Hongmei Jing14, Rui Huang15, Lihua Qiu16, Ying Li17, Wuhan Hui18, Meifang Zheng19, Yi Wang Sr, PhD20, Xiuhua Sun, MD21, Tianmo Sun22, Jianyong Li, MD23
1 Shengjing Hospital of China Medical University, Shenyang, China
2 Henan Cancer Hospital, Zhengzhou, China
3 the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
4 Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sci, Tianjin, China
5 Nanfang Hospital of Southern Medical University, Guangzhou, China
6 Ruijin Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
7 The First Hospital of Jilin University, Changchun, China
8 Wu Xi People’s Hospital, Wuxi, China
9 Chongqing University Cancer Hospital, Chongqing, China
10 The First Affiliated Hospital of USTC, Hefei, China
11 Shanxi Cancer hospital, Taiyuan, China
12 Yichang Central People's Hospital, Yichang, China
13 Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China
14 Peking University Third Hospital, Beijing, China
15 Zhujiang Hospital, Southern Medical University, Guangzhou, China
16 Tianjin Medical University Cancer Hospital, Tianjin, China
17 Shandong Provincial Hospital, Jinan, China
18 Xuanwu Hospital, Capital Medical University, Beijing, China
19 Linyi Cancer Hospital, Linyi, China
20 Shaanxi Provincial People's Hospital, Xian, China
21 The Second Hospital of Dalian Medical University, Dalian, China
22 Dizal Pharmaceutical, Beijing, China, Beijing, China
23 the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Background

Birelentinib (DZD8586) is a LYN/BTK dual inhibitor designed to block both BTK-dependent and BTK-independent BCR signalling pathways. In TAI-SHAN8 study (NCT06539182; CTR20240120), preliminary tumor responses were observed with Birelentinib treatment in patients with relapse/refractory (r/r) CLL/SLL who failed from front-line therapies, including covalent BTK inhibitors (cBTKi), non-covalent BTK inhibitors (ncBTKi) and BTK degraders. Building on this established clinical foundation and the rationale for earlier intervention, an expansion cohort was initiated to evaluate the efficacy and safety of Birelentinib monotherapy in treatment-naïve (TN) patients. Here, we report the preliminary efficacy and safety data from TN cohort alongside the updated long-term follow-up results among r/r patients.

Methods

Patients with CLL/SLL enrolled in TAI-SHAN8 were analysed separately for efficacy and safety in TN and r/r populations, with ongoing long-term follow-up. Tumor response was assessed by investigators per iwCLL 2018 or Lugano 2014 criteria, as applicable. 

Results

As of June 12, 2026, a total of 80 patients (r/r population, N=60; treatment naïve, N=20) received Birelentinib treatment at doses ranging from 25 mg to 75 mg once daily (QD) (25 mg, n=3; 50 mg, n=62; 75 mg, n=15). All TN patients received Birelentinib at 50 mg. Based on safety and efficacy data, the recommended phase 3 dose (RP3D) was determined as 50 mg QD. Here we reported efficacy and safety data at the RP3D.

For the 20 TN patients, the median age was 65 years, 50.0% were male, and 75.0% had an ECOG score of 1 or 2. High-risk genetic features included unmutated IGHV (12.5%), del(17p) and/or TP53 mutations (25.0%), and complex karyotype (35.7%). Baseline demographic characteristics of the r/r patients were comparable with those of the TN patients. The median lines of prior therapies for r/r patients was 2 (range: 1-5). The types of prior therapies included BTK-targeted agents (85.7% cBTKi, 7.1% ncBTKi and 4.8% BTK degrader), BCL-2 inhibitor (28.6%), and chemoimmunotherapy (45.2%). BTK mutations comprising kinase proficient, kinase impaired variants and del(17p) and/or TP53 mutation was detected.

In the TN efficacy analysis set (N=19), Birelentinib showed durable remissions with an ORR of 89.5% (95% CI: 66.9-98.7). An ORR of 100% was observed in patients with baseline del(17p) and/or TP53 mutations, as well as those with a complex karyotype. With median follow-up of 4.7 months, the median duration of response (DoR) was not reached, with 94.1% of responders still ongoing with Birelentinib treatment, and the longest DoR reached ≥9.0 months. With median follow-up of 8.3 months, 94.7% of patients had not experienced disease progression or death, with 9-month progression-free survival (PFS) rate of 94.1%.

In the r/r efficacy analysis set at the RP3D (N=37), sustained tumor responses and durable remissions were observed with an ORR of 70.3%, regardless of prior treatment or BTK mutation status. With median follow-up of 9.4 months, the median DoR was 20.1 months. Notably, 65.4% of responders still ongoing with Birelentinib treatment, with the longest DoR exceeding 21.0 months. With median follow-up of 11.3 months, the PFS rates were 63.7% at 9-month.

Birelentinib at 50 mg was well tolerated in both TN and r/r populations, with no new safety signals identified. Common (≥2 events) drug-related TEAEs with grade ≥3 in both groups were thrombocytopenia and neutropenia, with pneumonia additionally observed only in the r/r population. No febrile neutropenia, major bleeding, or atrial fibrillation was reported. Drug-related TEAEs leading to dose reduction occurred <17% of patients, and few patients discontinued treatment due to drug-related TEAEs. No drug-related TEAE-related death was reported. 

Conclusion

Birelentinib demonstrated encouraging anti-tumor activity and durable responses with well tolerated and manageable safety profile in both heavily TN and pre-treated CLL/SLL patients. Detailed findings will be presented at the meeting. Leveraging the proven monotherapy data of Birelentinib from this trial, combination regimens incorporating Birelentinib are being evaluated in TN patients, and a global phase III randomized study (NCT07139873) is ongoing to compare antitumor efficacy of Birelentinib versus investigator’s choice in r/r patients.

Wei Yang: No relevant conflicts of interest to declare.